Abion Successfully Concludes BioUSA... Discusses Technology Licensing and Investment Attraction with Global Big Pharma
Abion announced on the 7th that it attended BioUSA held in San Diego, USA, from the 3rd to the 6th (local time) to discuss licensing out (LO) and investment attraction with global big pharma companies.
BioUSA, hosted by the Biotechnology Innovation Organization (BIO) in the United States, is considered the world's largest pharmaceutical and biotechnology industry conference. This year, more than 1,500 pharmaceutical and biotech companies and 20,000 industry professionals participated.
At BioUSA, Abion promoted its pipeline research and development achievements and held partnering sessions with global big pharma companies. In particular, it shared clinical result updates of Babamekip (ABN401), which received significant attention at the American Society of Clinical Oncology (ASCO), and provided technical explanations on ABN202 and ABN501.
A company representative said, “There was an influx of inquiries regarding licensing out and investment proposals for Babamekip, which showed higher efficacy compared to global competitive drugs, as well as ABN501, being developed as a first-in-class innovative new drug, and ABN202, an antibody-drug conjugate (ADC) overcoming resistance and limitations.” He added, “It was a meaningful time to explore various business collaboration opportunities in the global market.”
Hot Picks Today
An Average of 1.4 Billion Won in Taxes per Person, Including 'Super Chats'... 23.9 Billion Won Imposed on 17 YouTubers Last Year
- She Was Not Punished for Drunk Driving... Court Rules Woman Who Drove to Escape Sexual Assault Not Criminally Liable
- Micron Holds the Fate of Semiconductor Stocks After Chuseok, Could Trigger a New Rally for Samsung Electronics and SK hynix [Weekend Money]
- Ruling and Opposition Parties Clash Over Confidential Repatriation of North Korean POWs: "Protecting Individuals" vs. "Appeasing the North"
- Who Is the Woman Next to Ivanka? Trump’s Granddaughter Who Sang in Chinese for Xi Jinping 9 Years Ago
Earlier, from the 31st of last month to the 4th (local time), Abion announced the cutoff results of the Phase 2 clinical trial of Babamekip at ASCO held in Chicago, USA. Babamekip's objective response rate was 54%, significantly surpassing the marketed drugs Tabrecta (48%) and Tepmeco (43%), and the treatment-related adverse events (TRAE) of grade 3 or higher were 10%, overwhelmingly lower than the 28-37.6% of competing drugs. This evaluation increased the possibility of Babamekip becoming the best-in-class new drug in its category.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
